The FKBP3 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population designed for loss-of-function studies of the FKBP3 gene in a B-lymphocyte background. This product provides a heterogeneous knockout model generated by CRISPR/Cas9-mediated gene disruption, allowing researchers to investigate the functional consequences of FKBP3 deficiency without clonal selection.
The parental Raji cell line is a lymphoblastoid B-cell line originating from a Burkitt’s lymphoma patient. Raji cells are positive for Epstein-Barr virus (EBV) and bear the t(8;14) chromosomal translocation, which places the c-MYC oncogene under the control of immunoglobulin heavy-chain enhancers, resulting in constitutive c-MYC overexpression. As a model system, Raji cells are extensively used to study B-cell malignancies, humoral immune responses, and the molecular basis of lymphomagenesis.
FKBP3 (FKBP25) is a peptidyl-prolyl cis-trans isomerase that binds the immunosuppressive drugs FK506 and rapamycin. It directly interacts with histone deacetylases HDAC1 and HDAC2 via the transcription factor YY1, forming complexes that modulate chromatin structure and gene expression. This regulatory role implicates FKBP3 in multiple signaling pathways, including mTOR signaling downstream of growth factor receptors, the NF-??B pathway, and HDAC-associated chromatin remodeling. Transcription of FKBP3 is regulated by c-MYC, NF-??B, SP1, and AP-1, while its downstream effects include altered histone H3 and H4 acetylation, transcriptional control of the cyclin-dependent kinase inhibitor p21 (CDKN1A), and regulation of the pro-apoptotic protein BAX. FKBP3 also interacts with minichromosome maintenance (MCM) proteins, linking it to DNA replication control.
In the Raji B-cell background, constitutive c-MYC activity imposes a heightened reliance on chromatin and transcriptional regulatory networks, making FKBP3 a critical node. Disruption of FKBP3 is anticipated to disrupt the assembly or function of HDAC1/2-YY1 repressor complexes, leading to changes in histone acetylation at gene promoters and subsequent deregulation of cell cycle (via p21) and apoptosis (via BAX). This model thus offers a platform to dissect the intersection between c-MYC-driven oncogenesis and epigenetic control mechanisms, particularly in the context of B-cell lymphoma biology.
The FKBP3 Knockout Raji Polyclonal Cells are suitable for a broad range of assays, including Western blotting to confirm protein loss, RT-qPCR for transcript analysis, chromatin immunoprecipitation (ChIP) to assess histone modifications, apoptosis and cell cycle analyses, co-immunoprecipitation of HDAC-containing complexes, and drug sensitivity profiling with HDAC inhibitors or immunosuppressants. Key research applications include mechanistic studies of B-cell lymphoma, screening of epigenetic therapeutics, investigation of B-cell receptor signaling cascades, and elucidation of FK506/rapamycin mechanisms of action. For additional information or technical inquiries, please contact Ascent Research.
